XORTX Therapeutics Inc. develops therapies for gout and progressive kidney disease, with programs that include XRx-026 for gout, XRx-008 for autosomal dominant polycystic kidney disease, XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections, and XRx-225 for Type 2 diabetic nephropathy. The company also holds the VB4-P5 kidney anti-fibrotic program, a pre-IND asset targeting rare and prevalent forms of kidney disease.
Company announcements cover clinical and preclinical pipeline development, acquired kidney-disease assets, share consolidations, Nasdaq and TSX Venture Exchange listing matters, annual meeting results, board elections, auditor appointments, stock option plan approvals, and other governance actions tied to its public-company status.
XORTX Therapeutics (XRTX) plans to submit an Investigational New Drug (IND) application to the U.S. FDA in the fourth quarter of 2026 for its XRx-026 gout program using the XORLO™ formulation of oxypurinol. This is intended to advance the company toward a future New Drug Application (NDA) filing and potential U.S. marketing approval.
The development plan includes FDA meetings, a two-part XRX-OXY-102 clinical trial to assess pharmacokinetics and efficacy, and manufacturing a first-year commercial supply of XORLO™. If XRX-OXY-102 is successfully completed, XORTX anticipates requesting a pre-NDA meeting and targeting an NDA submission in approximately one year, subject to sufficient funding and timely trial completion. Based on prior peak net sales of febuxostat, the company estimates XRx-026 addresses an approximate US$700 million annual U.S. gout market opportunity.
XORTX Therapeutics (XRTX) has initiated contract manufacturing of GMP oxypurinol drug substance and commercial-scale XORLO™ tablets to support its XRx-026 gout program. This work will supply the planned two-part XRX-OXY-102 clinical study and generate tablet batches representative of material intended for future US FDA marketing approval. Production of pure oxypurinol, the active pharmaceutical ingredient in XORLO™, has begun using the company’s proprietary synthetic pathway, and XORTX is collaborating with a contract manufacturing partner on commercial drug batches. Validation and stability data from this manufacturing are expected to support a future New Drug Application, which the company describes as a strategic priority for advancing XORLO™ as an alternative xanthine oxidase inhibitor therapy for individuals with gout.
XORTX Therapeutics (NASDAQ:XRTX) terminated its investor relations and marketing agreement with IR Agency, effective August 7, 2026, rescinding the arrangement and discontinuing all related services. The original 90‑day agreement, tied to a May 2026 US$5 million public offering, had allocated US$2.5 million in advance marketing fees that were subsequently returned to XORTX.
The company has postponed this investor relations program while it completes its voluntary delisting from the TSX Venture Exchange, which it expects to take effect on September 1, 2026, subject to TSXV approval. On the same date, Computershare Investor Services will replace TSX Trust Company as transfer agent. XORTX also disclosed that US$240,000 in aggregate cash finder’s fees were paid in connection with its April 13, 2026 acquisition of Vectus Biosystems’ renal anti‑fibrotic therapeutic program.
XORTX Therapeutics (NASDAQ: XRTX) announced that board member and chairman Anthony Giovinazzo has stepped down from the board of directors for personal reasons and to pursue other interests. Co-CEO Dr. Allen Davidoff expressed appreciation for Giovinazzo’s leadership, ethics and committee work over several years.
XORTX is a late-stage clinical pharmaceutical company developing therapies targeting gout and progressive kidney disease. Its pipeline includes XRx-026 for gout, XRx-008 for ADPKD, XRx-101 for acute kidney and organ injury linked to respiratory virus infections, and early-stage programs XRx-225 and VB4-P5 for various kidney diseases.
XORTX Therapeutics (NASDAQ: XRTX) announced the appointment of Depesh Narotam as an independent member of its board of directors, effective July 27, 2026. The board also determined his independence under Nasdaq listing standards and Canadian securities laws.
Mr. Narotam, age 43, joins the Compensation, Governance and Nominating Committee. He has over 20 years of experience in financial services, with expertise in debt financing, strategic lending solutions, market expansion and partnerships. He currently serves as a Mortgage Development Manager at Vancity and previously spent 16 years at Westminster Savings Credit Union (now Prospera Credit Union). XORTX is a late-stage clinical pharmaceutical company developing therapies for gout and progressive kidney disease, including programs XRx-026, XRx-008, XRx-101, XRx-225 and VB4-P5.
XORTX Therapeutics (NASDAQ:XRTX) issued a corporate update on June 15, 2026 and appointed Mika Grasso as co-CEO, responsible for finance and public markets. The company is preparing an IND for its lead gout program XRx-026/XORLO, planning a two-part XRX-OXY-102 bridging study to support a 505(b)(2) NDA targeting gout patients intolerant to allopurinol, a US $700 million market. XORTX also outlines plans to pursue NDA submission, including potential accelerated approval, for XRx-008 in ADPKD and aims to advance its gout program toward marketing approval over the next 18 months.
XORTX (NASDAQ:XRTX) elected to voluntarily delist its common shares from the TSX Venture Exchange following a strategic review of dual-listing costs and regulatory requirements. The company expects benefits including lower exchange, legal and accounting fees, streamlined financing and greater management focus on advancing its XRx-026 gout program.
Shares will continue trading on Nasdaq, no shareholder action is required, and XORTX remains a reporting issuer in Alberta, British Columbia and Ontario.
XORTX (NASDAQ:XRTX) closed a public offering of 2,659,574 common shares or pre-funded warrants at US$1.88, raising US$5 million in gross proceeds. The financing, still subject to final TSX Venture Exchange approval, will fund working capital, general corporate purposes, and investor relations activities.
E.F. Hutton & Co. acted as exclusive placement agent, earning a 4% (US$200,000) cash commission. According to the company, US$2.5 million of proceeds will be paid to IR Agency LLC for marketing and advertising services.
XORTX Therapeutics (NASDAQ:XRTX) priced a public offering of 2,659,574 common shares or pre-funded warrants at US$1.88 per share for expected gross proceeds of US$5 million before fees and expenses.
The pre-funded warrants are immediately exercisable at US$0.0001 and the offering is expected to close on or about May 15, 2026, subject to customary conditions and regulatory approvals.
XORTX (NASDAQ: XRTX) received a Nasdaq letter of compliance on April 20, 2026, curing a prior deficiency under Nasdaq Rule 5550(a)(2) that requires a US$1.00 minimum bid price.
Following a 1-for-5 reverse share split implemented April 6, 2026, the company’s shares traded at or above US$1.00 for 10 consecutive trading days, meeting the requirement on April 17, 2026.